Amgen (Nasdaq: AMGN) announced the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and safety ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE